Arbutus Biopharma Corporation

NASDAQ:ABUS

Biotechnology

Healthcare
$4.11 +1.13%

+$0.05 today

Market cap
$630.03M
Beta
0.63
P/E (TTM)
5.4
EPS (TTM)
$0.83
52W Low $3.04High $5.10

Volume 2.90M

Average 1.76M

ABUS Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Arbutus Biopharma CorporationNASDAQ: ABUS

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue remains negative

Q1 FY2026 deferred revenue was $0, compared with $6.76M a year earlier.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q1 FY2026, down 5.8 pp from a year earlier.
  • Deferred revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
Year agoMar 2025
$6.76M-100.0% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Deferred Revenue vs competitors

How ABUS compares with its peers on the latest reported figures

  • ABUS's Mar 2026 deferred revenue of $0 is the 4th highest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of -100.0% is the 4th highest of 6, against a peer median of -73.4%.
  • Deferred revenue amounts to 0.0% of total assets for ABUS, versus a peer median of 0.0%.
ABUS Competitors Peer median
Deferred Revenue for ABUS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ARWRArrowhead Pharmaceuticals, Inc.Sep 2026$91.65M +3720.3%+373.0%5.3%
ASMBAssembly Biosciences, Inc.Mar 2026$29.08M -28.8%—12.3%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$4.01M -73.4%-51.4%0.1%
ABUSArbutus Biopharma CorporationMar 2026$0 -100.0%—0.0%
VIRVir Biotechnology, Inc.Mar 2026$0 -100.0%—0.0%
SLNSilence Therapeutics plcMar 2026$0 -100.0%—0.0%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
BNTCBenitec Biopharma Inc.Mar 2026$0 ——0.0%
Peer median (excluding ABUS) $0-73.4%+160.8%0.0%

Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents109.28M30.78M26.29M36.33M18.01M
Short-term Investments46.04M116.14M99.72M86.29M73.46M
Net Receivables899K1.35M1.78M2.41M1.75M
Inventory00000
Other Current Assets02.87M4.25M2.28M1.24M
Total Current Assets160.66M151.14M132.03M127.32M94.46M
Property, Plant & Equipment (Net)8.07M6.81M6.09M4.36M32K
Goodwill00000
Intangible Assets00000
Long-term Investments35.69M37.36M6.28M00
Tax Assets00000
Other Non-current Assets61K103K034K130K
Total Non-current Assets43.82M44.28M12.37M4.39M162K
Total Assets204.49M195.42M144.4M131.71M94.62M
Account Payables3.17M3.52M3.22M2.32M1.17M
Short-term Debt383K372K00547K
Tax Payables00000
Deferred Revenue016.46M11.79M7.57M0
Other Current Liabilities3.39M8.78M3.7M02.13M
Total Current Liabilities11.22M32.86M22.49M15.62M6.01M
Long-term Debt16.3M10.37M6.95M4.83M3.44M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)06M02.86M0
Other Non-current Liabilities5.3M7.53M7.6M10.23M8.4M
Total Non-current Liabilities23.83M25.71M15.9M18.72M12.04M
Total Liabilities35.05M58.57M38.38M34.34M18.04M
Common Stock1.29B1.32B1.35B1.41B1.42B
Retained Earnings(1.13B)(1.2B)(1.28B)(1.35B)(1.38B)
Accumulated OCI(48.33M)(50.49M)(48.42M)(48.14M)(48.1M)
Other Stockholders Equity(1)0000
Minority Interest00000
Total Equity169.44M136.85M106.02M97.37M76.58M
Total Debt18.91M12.55M8.72M6.12M4.19M
Net Debt(90.37M)(18.22M)(17.56M)(30.21M)(13.82M)

Arbutus Biopharma Corporation

NASDAQ:ABUS

Intrinsic Alpha fair value

Locked

Current Price

$4.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.